Atlanta – – September 15, 2026 -- OrderlyMeds and Veo Health have launched a partnership that lets weight-loss patients track biological changes happening beneath the scale, not just the number on it.
Two new membership tiers track more than 60 biomarkers
OrderlyMeds customers can now access Veo Core, which screens 60-plus biomarkers with AI-powered insights, or Veo Pro, which expands to 80-plus biomarkers and adds physician consultations, health-advisor sessions and a personalized action plan. Veo Health members, meanwhile, get discounted access to OrderlyMeds' prescribing and clinical network.
The deal links prescribing, lab testing and coaching into one pipeline
Veo Health brings a national lab and mobile phlebotomy network, DEXA body-composition scans, wearable-device integrations and concierge clinical experts. OrderlyMeds contributes its telemedicine prescribing, coaching and clinical infrastructure. Together, the companies describe the arc as measure, understand, treat, monitor and optimize.
OrderlyMeds says more than 125,000 customers have already used its platform
OrderlyMeds connects patients with licensed physicians in all 50 states to access prescription GLP-1 medications, including compounded and brand-name treatments. The company states its customers have collectively lost more than 1 million pounds, though individual results vary. Compounded GLP-1 medications used through the platform are not FDA-approved and are not substitutes for FDA-approved drugs; they are prescribed based on an individualized medical determination by a licensed provider.
Executives frame the deal as prevention, not just weight loss
"At Orderly, we believe the best treatment is prevention," said Chris Spears, CEO of Orderly Wellness Corporation. Veo Health CEO David Harvey said the goal is to use the weight-loss journey as a catalyst for broader, longer-term health improvements.